13.57  -0.75 (-5.24%)		11-20 16:00
Open: 14.56 High: 14.94 Volume: 1,018,393		Pre. Close: 14.32 Low: 13.52 Market Cap: 1,128(M)

Short term
Mid term
Targets	6-month :	17.5	1-year :	19.8
Resists	First :	14.98	Second :	16.95
Pivot price	13.15
Supports	First :	11.78	Second :	9.8
MAs	MA(5) :	13.7	MA(20) :	13.4
	MA(100) :	11.07	MA(250) :	7.01
MACD	MACD :	-0.1	Signal :	-0.2
%K %D	K(14,3) :	71.4	D(3) :	73
RSI	RSI(14): 51.2
52-week	High :	16.95	Low :	2.59

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ AMLX ] has closed below upper band by 35.8%. Bollinger Bands are 7.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	14.96 - 15.04	15.04 - 15.1
Low:	13.36 - 13.43	13.43 - 13.49
Close:	13.46 - 13.58	13.58 - 13.67

Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Sun, 16 Nov 2025
Amylyx Pharmaceuticals (AMLX): Valuation Insights Following Improved Q3 2025 Financial Performance - simplywall.st

Thu, 13 Nov 2025
Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Amylyx Pharmaceuticals, Inc. – AMLX - Business Wire

Fri, 07 Nov 2025
December 2026 Options Now Available For Amylyx Pharmaceuticals (AMLX) - Nasdaq

Fri, 07 Nov 2025
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q3 2025 Earnings Call Transcript - Insider Monkey

Fri, 07 Nov 2025
Amylyx Pharmaceuticals Inc (AMLX): A Strategic SWOT Insight - GuruFocus

Thu, 06 Nov 2025
Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, - GlobeNewswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	110 (M)
Held by Insiders	7.406e+007 (%)
Held by Institutions	7.6 (%)
Shares Short	10,070 (K)
Shares Short P.Month	0 (K)

EPS	-1.5676e+008
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	23 %
Return on Assets (ttm)	660.1 %
Return on Equity (ttm)	-32.1 %
Qtrly Rev. Growth	-665000 %
Gross Profit (p.s.)	0
Sales Per Share	5.85
EBITDA (p.s.)	-1.18
Qtrly Earnings Growth	-1.8 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-154 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	2.31
Price to Cash Flow	-1.48

Dividend	0
Forward Dividend	1.045e+007
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.